228) ther individuals presenting inflammation (disease-positive or D+) can be distinguish |
229) PAF estimates the proportion of the disease or condition that would not occur |
230) are different manifestations of the same disease or if these conditions are in some |
231) Other systemic causes such as renal disease or liver disease are much rarer. |
232) Dementia, heart disease, or cerebrovascular diseases were |
233) including their developmental status and disease state as well as the pharmaceutica |
234) gement strategies have been shown to slow disease state progression or improve long- |
235) We review this disease state with respect to epidemiology |
236) be expected to provide about a patient's disease state. |
237) ormation" between the test result and the disease state. |
238) rn of a patient with probable Alzheimer's disease (AD) and Capgras syndrome was comp |
239) Recent research on Alzheimer's disease (AD) has shown that the altered st |
240) Alzheimer's disease (AD) is a neurodegenerative disord |
241) is of late onset and sporadic Alzheimer's disease (AD). |
242) Several animal models for Huntington's disease (HD) have been created in order to |
243) Huntington's disease (HD) is a devastating autosomal do |
244) Huntington's disease (HD) is a devastating inherited ne |
245) D) and symptomatic (symp-HD) Huntington's disease (HD). |
246) e eligibility for patients with Parkinson disease (PD) by ascertaining which variabl |
247) subjected to ligature-induced periodontal disease (PD) in the first left inferior mo |
248) Parkinson's disease (PD) is the second most common neu |
249) PPN), is severely affected by Parkinson's disease (PD) pathology and is regarded a p |
250) ms of PA which are more likely to improve disease activity and functional status. |
251) gy that is based on regular assessment of disease activity by using objective clinic |
252) Together with the equally high rate of disease activity indices in both genders, |
253) would have prevented the reoccurrence of disease activity. |
254) might be associated with cancer risk and disease outcome. |
255) might be associated with cancer risk and disease outcome. |
256) patients subgroup at high risk of a poor disease outcome. |
257) patients who are at a high risk of a poor disease outcome. |
258) les, clinical manifestations, HLA status, disease severity, functional capacities, q |
259) e associated with younger age and greater disease severity, less internal locus of c |
260) severe impact on HRQoL (DLQI ≥ 10) were disease severity, single status, working s |
|